Skip to main content

Table 3 Univariate and multivariate analysis of prognostic factors for PFS in patients with DLBCL

From: Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis

Parameters Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Age (>60 vs ≤60) 1.282 (0.745–2.204) 0.370   
Sex (male vs female) 0.927 (0.552–1.555) 0.773   
B symptoms (present vs absent) 1.421 (0.815–2.480) 0.216   
LDH (>ULN vs normal) 2.260 (1.329–3.843) 0.003   
ECOG score (2-4 vs 0-1) 2.111 (1.228–3.630) 0.007   
Ann Arbor Stage (III-IV vs I-II) 2.253 (1.214–4.179) 0.010   
Extranodal disease (>1 vs ≤1) 2.063 (1.226–3.472) 0.006   
IPI   <0.001   <0.001
 Low risk (0-1) reference   reference  
 Low-intermediate risk (2) 1.592 (0.726–3.490) 0.245 1.592 (0.726–3.490) 0.245
 High-intermediate risk (3) 4.238 (2.127–8.444) <0.001 4.238 (2.127–8.444) <0.001
 High risk (4-5) 3.140 (1.406–7.012) 0.005 3.140 (1.406–7.012) 0.005
Subtype (GCB vs non-GCB) 1.151 (0.774–1.711) 0.487   
FFAs (high vs normal) 2.050 (1.193–3.525) 0.009